Anthera Takes A "Haircut" And Delays Its Planned Initial Stock Offering
The biotech is not 'de-risked' enough to get the pricing it sought, as investors can be choosier, industry analyst says.
The biotech is not 'de-risked' enough to get the pricing it sought, as investors can be choosier, industry analyst says.